When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Encefalopatia de Wernicke

Última revisión: 21 Sep 2025
Última actualización: 17 Sep 2024

Resumen

Definición

History and exam

Key diagnostic factors

  • história de cirurgia gastrointestinal
  • lentidão mental, confusão, deficiência de concentração e apatia
  • sinais oculomotores
  • história de transtornos decorrentes do uso de bebidas alcoólicas
  • condições preexistentes que predispõem à desnutrição: por exemplo, HIV/AIDS, câncer, anorexia/bulimia, vômitos prolongados ou diarreia
  • tríade clássica: alterações no estado mental, oftalmoplegia e disfunção da marcha
Full details

Other diagnostic factors

  • irritabilidade leve
  • psicose aguda
  • coma
  • miose, anisocoria, dissociação luz-perto
  • papiledema, hemorragias retinianas
  • taquicardia ou hipotensão
  • hipotermia ou hipertermia
  • perda auditiva, crises epilépticas e paraparesia espástica
  • ataxia
Full details

Risk factors

  • transtornos decorrentes do uso de bebidas alcoólicas
  • Infecção por HIV e AIDS
  • câncer e tratamento com agentes quimioterápicos
  • desnutrição
  • história de cirurgia gastrointestinal
  • variantes genéticas associadas ao metabolismo e transporte alterados da tiamina
  • transplante de medula óssea
  • sexo masculino
Full details

Diagnostic investigations

1st investigations to order

  • tentativa terapêutica de tiamina parenteral
  • tiamina sérica
  • ressonância nuclear magnética (RNM) cranioencefálica
  • glicose sanguínea
  • Hemograma completo
  • eletrólitos séricos
  • função renal
  • TFHs
  • análise toxicológica
  • amônia sérica
  • nível de álcool no sangue
Full details

Investigations to consider

  • punção lombar
Full details

Treatment algorithm

ACUTE

suspeita de encefalopatia de Wernicke

ONGOING

alto risco de deficiência de tiamina

Contributors

Authors

Gregory S. Day, MD, MSc, MSCI, FAAN, FANA, FANA

Associate Professor of Neurology

Division Director, Behavioural Neurology

Mayo Clinic in Florida

Jacksonville

FL

Disclosures

GSD declares no competing interests directly relevant to this work. His research is supported by the National Institute of Health (U01AG057195, U01NS120901, U19AG032438). He serves as a consultant for Parabon NanoLabs, Inc. and as a topic editor (Dementia) for DynaMed (EBSCO). He is the co-project principal investigator for a clinical trial in anti-NMDAR encephalitis, which receives support from the National Institute of Neurological Disorders and Stroke (U01NS120901) and Amgen Pharmaceuticals, and a consultant for Arialys Therapeutics. He has developed and edited educational materials for Continuing Education, Inc. and Ionis Pharmaceuticals. GDS owns stock in ANI Pharmaceuticals. His institution has received support from Eli Lilly and Company for development and participation in an educational event promoting early diagnosis of symptomatic Alzheimer's disease, and in-kind contributions of radiotracer precursors for tau-PET neuroimaging in studies of memory and aging (via Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Company).

Acknowledgements

Dr Gregory S. Day would like to gratefully acknowledge Dr Abhay Moghekar, a previous contributor to this topic. AM is a medical advisory board member of the Hydrocephalus Association and was reimbursed for travel and airfare. AM was a consultant to Quest Diagnostics and Orbees Incorporation for market research, receiving payment for consulting. AM undertook research for Fujirebio Diagnostics and received a research grant to his lab at Johns Hopkins University.

Peer reviewers

Adrian Priesol, MD, FRCPC

Instructor

Massachusetts Eye and Ear Infirmary

Harvard Medical School

Boston

MA

Disclosures

AP declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Galvin R, Bråthen G, Ivashynka A, et al. Guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy. Eur J Neurol. 2010 Dec;17(12):1408-18.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Encefalopatia de Wernicke images
  • Differentials

    • Intoxicação alcoólica
    • Abstinência alcoólica
    • Encefalite viral
    More Differentials
  • Guidelines

    • Alcohol-use disorders: diagnosis and management of physical complications
    • Guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer